Want to see TARA full AI Analyst Report?
Top Page
Protara Therapeutics
(NASDAQ:TARA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▼(-36.06% Downside)
Action:Reiterated
Date:10/02/26
The score is primarily pressured by very weak financial performance (no revenue, widening losses, and ongoing cash burn), which increases financing and commercialization-duration risk. Technicals also detract due to a clear downtrend with negative momentum. Valuation provides only limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
Very low leverage
Very low leverage reduces financial risk and preserves flexibility because the company is not heavily dependent on debt financing. This gives management more room to fund development activities and respond to setbacks, although it does not eliminate the need for future capital.
Negative Factors
No revenue and pre-commercial status
The absence of revenue means the company has not yet demonstrated commercial demand or an operating revenue base to support research spending. As a pre-commercial biotech, it remains dependent on successful development and eventual commercialization before it can build recurring business cash flows.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Very low leverage reduces financial risk and preserves flexibility because the company is not heavily dependent on debt financing. This gives management more room to fund development activities and respond to setbacks, although it does not eliminate the need for future capital.
Read all positive factors
Protara Therapeutics (TARA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$145.97M
Dividend YieldN/A
Average Volume (3M)1.56M
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth17.06%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.36
Shares Outstanding59,095,490
10 Day Avg. Volume1,101,976
30 Day Avg. Volume1,559,467
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.04K
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$24.00Price Target Upside513.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Protara Therapeutics Business Overview & Revenue Model
Company Description
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncolog...
Protara Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -90.00K | -362.00K | 0.00 | -341.00K | 0.00 | 0.00 |
| EBITDA | -69.67M | -57.08M | -44.26M | -40.08M | -64.57M | -45.40M |
| Net Income | -70.02M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
Balance Sheet | ||||||
| Total Assets | 176.09M | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Cash, Cash Equivalents and Short-Term Investments | 17.08M | 155.55M | 170.29M | 65.58M | 84.37M | 91.23M |
| Total Debt | 2.75M | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Total Liabilities | 14.78M | 13.06M | 14.32M | 10.63M | 11.21M | 10.68M |
| Stockholders Equity | 161.31M | 196.41M | 167.13M | 68.32M | 102.08M | 161.91M |
Cash Flow | ||||||
| Free Cash Flow | -66.49M | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
| Operating Cash Flow | -66.13M | -56.37M | -35.81M | -37.56M | -26.46M | -34.50M |
| Investing Cash Flow | -30.38M | -139.49M | 19.16M | 53.11M | 14.95M | -98.19M |
| Financing Cash Flow | 82.09M | 82.72M | 139.87M | -91.00K | -90.00K | -228.00K |
Protara Therapeutics Technical Analysis
Negative
3.91
Price Trends
3.28
Negative
3.65
Negative
4.60
Negative
Market Momentum
-0.26
Negative
37.06
Neutral
28.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARA, the sentiment is Negative. The current price of 3.91 is above the 20-day moving average (MA) of 2.56, above the 50-day MA of 3.28, and below the 200-day MA of 4.60, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 28.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TARA.
Protara Therapeutics Risk Analysis
Protara Therapeutics disclosed 62 risk factors in its most recent earnings report. Protara Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protara Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $116.47M | -3.62 | 168.68% | ― | ― | 67.07% | |
46 Neutral | $228.99M | -4.33 | -99.17% | ― | -33.68% | 4.48% | |
46 Neutral | $86.81M | -0.57 | -143.09% | ― | ― | -169.38% | |
44 Neutral | $145.97M | -1.82 | -41.72% | ― | ― | 17.06% | |
42 Neutral | $106.48M | -0.08 | 250.02% | ― | ― | -2012.66% | |
41 Neutral | $121.43M | -5.01 | -21.11% | ― | ― | 73.28% |
* Healthcare Sector Average
TARA
Protara Therapeutics
2.47
-2.73
-52.50%
NERV
Minerva Neurosciences
2.23
-2.00
-47.28%
AVXL
Anavex Life Sciences
1.31
-6.71
-83.67%
ACIU
AC Immune SA
2.25
-1.59
-41.41%
PMN
ProMIS Neurosciences
9.68
-0.72
-6.92%
NRXP
NRX Pharmaceuticals
2.69
-0.36
-11.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.